Abstract: The present invention discloses novel pentamidine analogues such as pentamidine analogs having the general formula: wherein: X is C, N, or —CH—CH—, Y is Y1 when X is N, and Y is Y1 and Y2 when X is C, or —CH—CH—, Y1, or Y1 and Y2 independently, are selected from H, hydroxyl, lower alkyl, lower alkoxy, halogen, nitro, amino, cyano or thiol, wherein the lower alkyl or alkoxy is optionally substituted with one or more of hydroxyl, halogen, nitro, amino, cyano, thiol, or a 5- or 6-membered aromatic or non-aromatic ring, optionally substituted with one or more of hydroxyl, lower alkyl, lower alkoxy, halogen, nitro, amino, cyano or thiol, wherein Y1 is not H when X is N; or Y1 is a 5- or 6-membered aromatic or non-aromatic ring, optionally substituted with one or more groups selected from hydroxyl, lower alkyl, lower alkoxy, halogen, nitro, amino, cyano, carboxy, or thiol, and Y2 is H, if present; or Y1 and Y2 together with X form a 5- to 8-membered hydrocarbon ring, optionally substituted with one or more g

Abstract: The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection, with obesity disorders are also disclosed.

Abstract: The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed.

Abstract: The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed.

Abstract: The present invention provides methods for the identification of agents, e.g., therapeutic agents, that inhibit Fatty Acid Transport 5 (FATP5) activity, and methods of treating diseases or conditions associated with FATP5 function, e.g., obesity, insulin resistance, type 2 diabetes, dyslipidemia, fatty liver disease, and cardiovascular disease. Further aspects of the invention provide a transgenic FATP5 non-human knockout mammal, e.g., mouse, useful for elucidating the function of FATP5 in intact animals whose genomes comprise a wild-type FATP5 gene.

Abstract: A four-stroke internal combustion engine is provided that is capable of use in many power tools, including those power tools subjected to tippable applications. There is provided within an engine housing, an oil reservoir and a valve chamber which independently communicate with a crank chamber. A system of strategically placed dividers and passageways within the engine housing appropriately directs lubricant within the engine housing so that the internal cavity of the engine is lubricated during use in any operational attitude, and so that the lubricant flows to and is held in the proper chambers during storage. There is also provided a breather arrangement for an internal combustion engine which includes a camshaft having a hollow passageway in communication with a crank chamber.

Abstract: A four-stroke internal combustion engine is provided that is capable of use in many power tools, including those power tools subjected to tippable applications. There is provided within an engine housing an oil reservoir and a valve chamber which independently communicate with a crank chamber. A strategically placed divider and passageway, located within the engine housing, appropriately direct lubricant within the engine housing so that the internal cavity of the engine is lubricated during use in various operating attitudes, and so that the fluid flows to and is held in the proper chambers of the engine housing during storage. There is also provided a breather arrangement for an internal combustion engine which includes a cam shaft having a hollow passageway in communication with the crank chamber and the air intake system of the engine.

Abstract: Methods for the purification of interleukin-12 (IL-12) is provided.